The Efficacy of Lansoprazole and Domperidone Combination on Intragastric and Intraesophageal Acidity

Neutec Ar-Ge San ve Tic

Status and phase

Completed

Phase 4

Conditions

Gastroesophageal Reflux Disease

Treatments

Drug: Lansoprazole/Domperidone

Study type

Interventional

Funder types

Industry

Identifiers

NCT02958046

Neu-01.13

Details and patient eligibility

About

The purpose of this study is to investigate the efficacy of lansoprazole combination with domperidone on intragastric acidity and intraesophageal acidity, GERD symptoms, impedance kinetics, gastric emptying in patients with gastroesophageal reflux disease (GERD).

Full description

Objectives of the trial to assess the efficacy of lansoprazole in combination with domperidone on gastric acidity, intraesophageal acidity, GERD symptoms, impedance kinetics and gastric emptying in patients with GERD.

24 hour pH measurement and gastric emptying test will be done at screening visit and after 7 days of drug treatment. Twelve patients will take one tablet for 7 days.

Enrollment

12 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diagnosis of GERD with symptoms (i.e. regurgitation, pyrosis) during last one year with at least 1 or more episodes a week
Age ≥ 18 years and <65 years
Helicobacter pylori (an infection) negative
Have a body mass index (BMI) between 18 and 33 kg/m²
pH>4 gastric exposure <25% on a 24-hour dual pH channel monitoring study performed prior to screening (normal intragastric pH +2SD)
Pathologic intraesophageal acidity exposure (DeMeester score >14.75 and/or >4% of pH<4 (at least 21 hours measured)

Exclusion criteria

Have food existence at stomach during upper GIS endoscopy, Barrett's stricture, GIS bleeding, malignite, and all type of GIS pathology to affects the study
Have allergy to the study drug or any of the excipients of the formulation
Must use of pain relieving medications (NSAIDs) during study, (paracetamol not excess of 2 gram/day can be used)
Use of any concomitant therapy which are drug affects the motility of GIS and acid secretion
Use of prostaglandin analogs and sucralfate
Have taken PPIs or H2-blockers within 7 days and prokinetic drugs within 3 days before entering the study
History of surgery of cholecystectomy
Abusing drugs or alcohol
Have a major psychiatric disease
Use of antidepressant (patient with minor depression or under controlled with drug can be included)
Have suppressed immune system or taken a immunosupressive treatment, including cortisone.
Have malabsorption, gastric outlet obstruction that affects the absorption of drug
Must use of drug ketoconazole, iron salts, digoxin, ampicilin esters , anticoagulants, antineoplastic agents
Women who are pregnant or of childbearing
Have gastroparesis
Current or a history of cancer, with the exception of fully excised skin carcinoma (Malign Melanoma will be excluded).
Have severe concomitant disease (i.e. uncontrolled or insuline dependent diabetes mellitus, symptomatic bladder stone (patients have asemptomatic, not undergone colesistit, stone <3cm and polib <1cm can be included), active or unhealed gastric or duodenum ulcer, Zollinger Ellison syndrome, primary esophageal motility disorder, pancreatitis, inflammatory bowel disease, chronic hepatic disease, severe lung disease, uncontrolled kidney failure, cardiac failure, cerebrovascular disease, epilepsy) which affects the conduct and result of study.